73 related articles for article (PubMed ID: 3005399)
1. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
[TBL] [Abstract][Full Text] [Related]
3. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
4. Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K; Kuribayashi K; Saito K
Cancer Immunol Immunother; 1989; 29(2):79-86. PubMed ID: 2497980
[TBL] [Abstract][Full Text] [Related]
5. Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients.
Liberati AM; De Angelis V; Fizzotti M; Schippa M; Cecchini M; Adiuto D; Di Clemente F; Palmisano L; Micozzi E; Zuccaccia M
Cancer Immunol Immunother; 1994 May; 38(5):323-31. PubMed ID: 7512888
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
Anderson PM; Bach FH; Ochoa AC
Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
[TBL] [Abstract][Full Text] [Related]
7. Production of multiple cytokines by clones of human large granular lymphocytes.
Allavena P; Scala G; Djeu JY; Procopio AD; Oppenheim JJ; Herberman RB; Ortaldo JR
Cancer Immunol Immunother; 1985; 19(2):121-6. PubMed ID: 3921231
[TBL] [Abstract][Full Text] [Related]
8. Target cell induced activation of NK cells in vitro: cytokine production and enhancement of cytotoxic function.
Das S; Varalakshmi C; Kumari AL; Patel M; Khar A
Cancer Immunol Immunother; 2001 Oct; 50(8):428-36. PubMed ID: 11726137
[TBL] [Abstract][Full Text] [Related]
9. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas.
Whiteside TL; Miescher S; Hurlimann J; Moretta L; von Fliedner V
Cancer Immunol Immunother; 1986; 23(3):169-78. PubMed ID: 3024832
[TBL] [Abstract][Full Text] [Related]
10. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
Anderson TM; Ibayashi Y; Holmes EC; Golub SH
Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
[TBL] [Abstract][Full Text] [Related]
11. Lysis of small cell carcinoma of the lung tumor cell lines by gamma interferon-activated allogeneic peripheral blood mononuclear cells: abrogation of killing by pretreatment of tumor cells with gamma interferon.
Ball ED; Nichols KE; Pettengill OS; Sorenson GD; Fanger MW
Cancer Immunol Immunother; 1986; 22(3):211-6. PubMed ID: 3015408
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis.
Hauer J; Anderer FA
Cancer Immunol Immunother; 1993; 36(4):237-44. PubMed ID: 8439987
[TBL] [Abstract][Full Text] [Related]
13. Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.
Blomgren H
Cancer Immunol Immunother; 1989; 29(2):151-3. PubMed ID: 2720708
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 and interleukin-7 augment the cytolytic activity and expand the antitumor killing spectrum of alpha CD3-induced activated killer cells: potential use in the immunotherapy of non-immunogenic tumors.
Ting CC; Wang J; Yang Y
Cancer Immunol Immunother; 1996 Dec; 43(5):283-92. PubMed ID: 9024505
[TBL] [Abstract][Full Text] [Related]
15. Modulation of natural killer activity by thymosin alpha 1 and interferon.
Favalli C; Jezzi T; Mastino A; Rinaldi-Garaci C; Riccardi C; Garaci E
Cancer Immunol Immunother; 1985; 20(3):189-92. PubMed ID: 3851698
[TBL] [Abstract][Full Text] [Related]
16. Endogeneous interferon alpha/beta produced by murine Kupffer cells augments liver-associated natural killing activity.
Werner-Wasik M; von Muenchhausen W; Nolan JP; Cohen SA
Cancer Immunol Immunother; 1989; 28(2):107-15. PubMed ID: 2917363
[TBL] [Abstract][Full Text] [Related]
17. A protein fraction from aged garlic extract enhances cytotoxicity and proliferation of human lymphocytes mediated by interleukin-2 and concanavalin A.
Morioka N; Sze LL; Morton DL; Irie RF
Cancer Immunol Immunother; 1993 Oct; 37(5):316-22. PubMed ID: 8402735
[TBL] [Abstract][Full Text] [Related]
18. Influence of human interferon-alpha therapy on cytotoxic functions of blood lymphocytes. Studies on lectin-dependent cellular cytotoxicity, antibody-dependent cellular cytotoxicity, and natural killer cell activity.
Einhorn S; Blomgren H; Strander H; Wasserman J
Cancer Immunol Immunother; 1983; 16(2):77-80. PubMed ID: 6559104
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy.
D'Atri S; Fuggetta MP; Giganti G; Tentori L; Roselli M; Nunziata C; Pastore S; Bonmassar E; De Vecchis L
Cancer Immunol Immunother; 1988; 27(2):163-70. PubMed ID: 3416325
[TBL] [Abstract][Full Text] [Related]
20. Defective interleukin-1 production by natural killer cells of patients with cancer.
Herman J; Kew MC; Rabson AR
Cancer Immunol Immunother; 1985; 19(2):148-53. PubMed ID: 2985238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
